Provided by Tiger Trade Technology Pte. Ltd.

Biogen

210.73
-1.7700-0.83%
Pre-market: 210.60-0.1300-0.06%07:27 EDT
Volume:694.67K
Turnover:146.79M
Market Cap:31.11B
PE:37.43
High:213.48
Open:210.50
Low:209.00
Close:212.50
52wk High:225.80
52wk Low:135.39
Shares:147.64M
Float Shares:147.31M
Volume Ratio:0.94
T/O Rate:0.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.63
EPS(LYR):8.79
ROE:4.58%
ROA:5.21%
PB:1.65
PE(LYR):23.97

Loading ...

Biogen to face questions on safety and dose response, says Stifel

TIPRANKS
·
Jul 14

Eisai, Biogen announce presentation of results from real-world LEADER study

TIPRANKS
·
Jul 14

Leqembi® Real-world Leader Study Presented at Aaic® 2026 Finds over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved over an Average of 17 Months of Treatment

THOMSON REUTERS
·
Jul 14

Movement Alert|Biogen Falls 7.06% in Regular Trading, Diranersen Phase 2 CELIA Full Data Reveals Missed Primary Endpoint Sparking Registration Path Concerns

Market Focus
·
Jul 14

Biogen Down over 7%, on Pace for Largest Percent Decrease Since November 2020

Dow Jones
·
Jul 14

Analysts Conflicted on These Healthcare Names: Biogen (BIIB) and TG Therapeutics (TGTX)

TIPRANKS
·
Jul 14

Biogen Shares Down 6.2% After Co's Experimental Alzheimer's Drug Misses Main Goal in Mid-stage Study

THOMSON REUTERS
·
Jul 14

Biogen announces expanded data from CELIA study evaluating diranersen

TIPRANKS
·
Jul 14

Biogen Plans Phase 3 Development of Alzheimer’s Tau Therapy Diranersen After Phase 2 Data

Reuters
·
Jul 14

Biogen - to Advance Diranersen into Confirmatory Phase 3 Development

THOMSON REUTERS
·
Jul 14

Biogen - Diranersen Shows 50–65% Mean Reduction in Csf Total Tau and Brain Tau Pathology

THOMSON REUTERS
·
Jul 14

Biogen Presents Phase 2 Celia Data at Aaic Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease

THOMSON REUTERS
·
Jul 14

Biogen's Alzheimer's Drug Lowers Toxic Protein, but Results were Mixed

Reuters
·
Jul 14

Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biogen (BIIB) and Cadrenal Therapeutics, Inc. (CVKD)

TIPRANKS
·
Jul 14

Piper Sandler Remains a Buy on Biogen (BIIB)

TIPRANKS
·
Jul 14

Canaccord Genuity Remains a Buy on Biogen (BIIB)

TIPRANKS
·
Jul 14

IQLIK Approval Seen as Commercial Enhancer, Not Fundamental Shift, as Biogen Neutral Rating and $200 Price Target Remain Unchanged

TIPRANKS
·
Jul 14

Is Biogen (BIIB) Fairly Valued On FDA Approval Of Its New Leqembi Autoinjector?

Simply Wall St.
·
Jul 14

Eisai Inc: Leqembi Iqlik Initiation Dosing Expected to be Available in U.S. Late August 2026

THOMSON REUTERS
·
Jul 14

FDA Approves Leqembi Iqlik® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease

THOMSON REUTERS
·
Jul 14